Werewolf Therapeutics, Inc.
HOWL
$0.63
-$0.03-4.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 1.14M | 1.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 1.14M | 1.89M |
| Cost of Revenue | 30.34M | 39.08M | 39.86M | 40.40M | 40.11M |
| Gross Profit | -30.34M | -39.08M | -39.86M | -39.26M | -38.22M |
| SG&A Expenses | 18.95M | 21.13M | 21.75M | 22.18M | 22.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.68M | 71.61M | 73.01M | 75.57M | 75.48M |
| Operating Income | -60.68M | -71.61M | -73.01M | -74.42M | -73.59M |
| Income Before Tax | -60.82M | -72.84M | -73.14M | -72.41M | -70.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.82 | -72.84 | -73.14 | -72.41 | -70.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.82M | -72.84M | -73.14M | -72.41M | -70.52M |
| EBIT | -60.68M | -71.61M | -73.01M | -74.42M | -73.59M |
| EBITDA | -59.04M | -69.93M | -71.28M | -72.65M | -71.78M |
| EPS Basic | -1.33 | -1.62 | -1.64 | -1.64 | -1.63 |
| Normalized Basic EPS | -0.83 | -1.01 | -1.03 | -1.02 | -1.01 |
| EPS Diluted | -1.36 | -1.62 | -1.64 | -1.67 | -1.65 |
| Normalized Diluted EPS | -0.83 | -1.01 | -1.03 | -1.01 | -1.01 |
| Average Basic Shares Outstanding | 184.04M | 180.09M | 177.99M | 176.53M | 173.31M |
| Average Diluted Shares Outstanding | 184.83M | 180.09M | 177.99M | 177.05M | 173.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |